OncoMatch/Clinical Trials/NCT05832827
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Is NCT05832827 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including MK-3475 and Lenvatinib for untreated advanced or recurrent thymic carcinomas.
Treatment: MK-3475 · Lenvatinib · Carboplatin · Paclitaxel — A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Biomarker criteria
Allowed: CD5 overexpression
preferred to be positive for CD5 or c-KIT by immunohistochemical staining
Allowed: KIT overexpression
preferred to be positive for CD5 or c-KIT by immunohistochemical staining
Disease stage
Required: Stage III, IVA, IVB (Masaoka-Koga)
unresectable advanced thymic carcinoma (equivalent to stage IVa or IVb of Masaoka-Koga classification), metastatic or recurrent ... Or, in the case of stage III Masaoka-Koga classification, patients who are judged to be incapable of radical resection ... Have measurable disease based on RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: vegfr inhibitor
Lab requirements
Blood counts
Adequate organ function as defined in the following table (Table 8). Specimens must be collected within 14 days prior to registration.
Kidney function
Adequate organ function as defined in the following table (Table 8). Specimens must be collected within 14 days prior to registration.
Liver function
Adequate organ function as defined in the following table (Table 8). Specimens must be collected within 14 days prior to registration.
Cardiac function
LVEF below institutional normal range (MUGA or ECHO) excluded; ECG QTcF > 480 ms excluded
Have adequate organ function as defined in the following table (Table 8). LVEF below the institutional normal range, as determined by MUGA or ECHO [excluded]. Patients with ECG QT correction interval prolongation or history of such prolongation (patients with QTcF > 480 ms) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05832827 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IVA or IVB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify